Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG0601 weekly rituximab plus CHOP versus standard R-CHOP in untreated CD20-positive diffuse large B-cell lymphoma
jRCTs031180139Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: complete response rate and progression-free survival. Started Jan 2008; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisolone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCTs031180139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180139.